North America Osteoporosis Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Bisphosphonate, Hormone Replacement Therapy, Selective Estrogen Receptor Modulator (SERMs), RANK ligand (RANKL) Inhibitor, and Others), By Route of Administration (Oral, and Parenteral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies) and Forecast, 2020-2027

Last Updated: February 10, 2025 | Format: PDF | Report ID: FBI104867

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. Prevalence of Osteoporosis, Key Countries, 2019
2. Technology Advances, Osteoporosis Market
3. New Product Launches, Key Players
4. Key Developments, Mergers, Acquisitions, etc.
5. Impact of Covid-19 on the Market
North America Osteoporosis Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Bisphosphonate
  2. Hormone Replacement Therapy
  3. Selective Estrogen Receptor Modulator (SERMs)
  4. RANK ligand (RANKL) Inhibitor
  5. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Cardiovascular
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospitals Pharmacies
  2. Retail Pharmacies & Stores
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Competitive Analysis
1. Key Industry Developments
2. Global Market Share Analysis (2019)
3. Company Profiles (Overview, Products, SWOT, Recent Developments, Strategies, Financials (based on availability))
  1. AbbVie Inc.
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  2. Eli Lilly and Company
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  3. Amgen Inc.
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  4. F. Hoffmann-La Roche Ltd
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  5. Novartis AG
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  6. Sanofi
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  7. Pfizer Inc.
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  8. Merck & Co., Inc.
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  9. GlaxoSmithKline plc
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  10. Alcon
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
  11. Other Prominent Player
    1. Overview,
    2. Products,
    3. SWOT,
    4. Recent Developments,
    5. Strategies,
    6. Financials (based on availability)
Strategic Recommendations